AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia AreataPRNewsWire • 06/29/26
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental VitiligoPRNewsWire • 06/29/26
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic DiseasePRNewsWire • 06/26/26
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree24/7 Wall Street • 06/25/26
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026PRNewsWire • 06/24/26
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE BuyoutZacks Investment Research • 06/23/26
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientsPRNewsWire • 06/23/26
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus InfectionPRNewsWire • 06/23/26
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque PsoriasisPRNewsWire • 06/23/26